Get the Stockscreener App
1.36
3.03%
0.04
Acrivon Therapeutics Inc stock is traded at $1.36, with a volume of 226.90K.
It is up +3.03% in the last 24 hours and down -2.16% over the past month.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
See More
Previous Close:
$1.32
Open:
$1.31
24h Volume:
226.90K
Relative Volume:
0.54
Market Cap:
$42.78M
Revenue:
-
Net Income/Loss:
$-69.00M
P/E Ratio:
-0.4892
EPS:
-2.78
Net Cash Flow:
$-55.26M
1W Performance:
+0.74%
1M Performance:
-2.16%
6M Performance:
-75.45%
1Y Performance:
-84.35%
1-Day Range:
$1.31
$1.415
1-Week Range:
$1.27
$1.435
52-Week Range:
$1.05
$10.16
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Name
Acrivon Therapeutics Inc
Sector
Industry
Phone
617-207-8979
Address
480 ARSENAL WAY, SUITE 100, WATERTOWN
Compare ACRV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.36 | 43.72M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-05-25 | Resumed | Piper Sandler | Overweight |
| Jan-31-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Apr-29-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-24 | Initiated | JMP Securities | Mkt Outperform |
| Dec-15-23 | Resumed | Jefferies | Buy |
| Oct-05-23 | Initiated | Maxim Group | Buy |
| Jun-02-23 | Initiated | Oppenheimer | Outperform |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Apr-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Apr-20-23 | Initiated | H.C. Wainwright | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Dec-12-22 | Initiated | Jefferies | Buy |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
View All
Acrivon Therapeutics Inc Stock (ACRV) Latest News
Is this a good reentry point in Acrivon Therapeutics Inc.Market Sentiment Report & Free Growth Oriented Trading Recommendations - Newser
Acrivon Therapeutics Inc. Recovery Likely Here’s What Data ShowsPortfolio Performance Report & High Win Rate Trade Tips - kangso.co.kr
Price Action Confirms Reversal in Acrivon Therapeutics Inc. TrendWeekly Stock Analysis & Consistent Income Trade Recommendations - classian.co.kr
ACR-368 OncoSignature assay gains FDA breakthrough status - MSN
Is Acrivon Therapeutics Inc. stock a good hedge against inflation2025 Market Outlook & Capital Efficient Trade Techniques - Newser
Using fundamentals and technicals on Acrivon Therapeutics Inc.July 2025 Snapshot & Reliable Entry Point Trade Alerts - Newser
Acrivon Therapeutics Inc. stock chart pattern explained2025 Technical Patterns & Consistent Income Trade Recommendations - Newser
Real time breakdown of Acrivon Therapeutics Inc. stock performance2025 Investor Takeaways & Real-Time Sentiment Analysis - Newser
What indicators show strength in Acrivon Therapeutics Inc.July 2025 Drop Watch & Comprehensive Market Scan Insights - Newser
Acrivon Therapeutics Inc. stock prediction for this weekMarket Activity Recap & Weekly Sector Rotation Insights - Newser
Visual analytics tools that track Acrivon Therapeutics Inc. performanceJuly 2025 Selloffs & Precise Swing Trade Alerts - Newser
Smart tools for monitoring Acrivon Therapeutics Inc.’s price actionWeekly Stock Recap & Low Risk Entry Point Guides - Newser
Full technical analysis of Acrivon Therapeutics Inc. stockJuly 2025 Catalysts & Fast Exit Strategy with Risk Control - Newser
What does recent volatility data suggest for Acrivon Therapeutics Inc.Earnings Trend Report & Expert Approved Momentum Ideas - Newser
Why Acrivon Therapeutics Inc. is moving todayRecession Risk & Weekly High Potential Stock Alerts - Newser
How to recover losses in Acrivon Therapeutics Inc. stockEarnings Summary Report & Consistent Income Trade Recommendations - Newser
How institutional ownership impacts Acrivon Therapeutics Inc. stockQuarterly Market Review & Capital Efficiency Focused Strategies - Newser
Can volume confirm reversal in Acrivon Therapeutics Inc.July 2025 Patterns & Risk Controlled Swing Alerts - Newser
Understanding Acrivon Therapeutics Inc.’s price movementJuly 2025 Action & Technical Pattern Based Buy Signals - Newser
Published on: 2025-08-19 01:37:39 - Newser
Best data tools to analyze Acrivon Therapeutics Inc. stockWeekly Risk Report & Consistent Income Trade Ideas - Newser
Relative strength of Acrivon Therapeutics Inc. in sector analysisTrade Signal Summary & AI Forecasted Entry/Exit Points - Newser
Acrivon Therapeutics Inc. Company Revenue and Profit Trends: A Deep Dive2025 Price Action Summary & Fast Entry Momentum Alerts - Newser
Acrivon Therapeutics’ SWOT analysis: precision medicine stock faces pivotal trials - Investing.com
Research Analysts Set Expectations for ACRV Q3 Earnings - Defense World
Momentum divergence signals in Acrivon Therapeutics Inc. chartWeekly Trade Review & High Win Rate Trade Alerts - Newser
Is Acrivon Therapeutics Inc. stock entering bullish territoryWeekly Risk Report & Weekly Top Gainers Trade List - Newser
Is Acrivon Therapeutics Inc. forming a double bottomQuarterly Performance Summary & Low Risk Entry Point Tips - 선데이타임즈
Historical volatility pattern of Acrivon Therapeutics Inc. visualizedOil Prices & Free Technical Pattern Based Buy Signals - Newser
Is Acrivon Therapeutics Inc. a potential multi baggerDip Buying & Technical Pattern Recognition Alerts - thegnnews.com
Is Acrivon Therapeutics Inc. stock a smart retirement pick2025 Price Targets & Weekly Momentum Stock Picks - newsyoung.net
Acrivon Therapeutics, Inc.: Promising Clinical Developments and Strong Financial Position Justify Buy Rating - TipRanks
Detecting support and resistance levels for Acrivon Therapeutics Inc.Quarterly Investment Review & Low Drawdown Momentum Ideas - Newser
Real time alert setup for Acrivon Therapeutics Inc. performanceMarket Volume Summary & Technical Pattern Alert System - Newser
Why Acrivon Therapeutics Inc. stock attracts strong analyst attentionWatch List & Weekly Momentum Picks - Newser
Short interest data insights for Acrivon Therapeutics Inc.Fed Meeting & Real-Time Buy Signal Alerts - Newser
Acrivon Therapeutics Inc Stock (ACRV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acrivon Therapeutics Inc Stock (ACRV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 10% Owner |
May 01 '25 |
Sale |
1.34 |
298,886 |
400,507 |
3,104,139 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 25 '25 |
Sale |
1.95 |
1,054,669 |
2,056,605 |
4,306,189 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 29 '25 |
Sale |
1.41 |
250,000 |
352,500 |
3,840,906 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 28 '25 |
Sale |
1.56 |
215,283 |
335,841 |
4,090,906 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):